UNSPSC 51182222: Ergometrine maleate

This classification denotes a serotonin antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YMH3D0ZJWV. European Medicines Agency schedules Ergometrine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01931MIG. Ergonovine maleate generally arises in the molecular formula C23H27N3O6. The term 'ergonovine maleate' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule ergometrine maleate under HS 29396100.

SMILES: C[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3C[NH]C4C3C(CCC4)C2=C1)C.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51182222 Ergometrine maleate is a Commodity code covering a specific pharmaceutical ingredient supplied through state and local cooperative purchasing agreements for healthcare facilities. State and local governments procure this product as part of broader generic pharmaceutical and over-the-counter (OTC) product contracts distributed across participating facilities, typically within multistate cooperative purchasing vehicles that coordinate procurement and pricing across member jurisdictions. The scope of work involves pharmaceutical manufacturers supplying products meeting FDA requirements, current Good Manufacturing Practices (cGMP), and Drug Supply Chain Security Act (DSCSA) compliance, with detailed product specification requirements including National Drug Codes (NDC), stock keeping units (SKUs), universal product codes (UPCs), strength, dosage form, packaging configurations, and manufacturing locations. Issuing bodies under this code are state procurement offices administering multistate cooperative purchasing alliances and the state and local government facilities participating in those cooperative agreements, not individual municipalities or school districts — the structure centralizes pharmaceutical procurement across multiple jurisdictions through a single contracting vehicle.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 with a response deadline of March 26, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products covering participating facilities in Minnesota, Oregon, and other member states. The RFP requires awarded vendors to distribute products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), with products available in the marketplace by May 15, 2026 and contract effectiveness on July 1, 2026. Evaluation weighting heavily favors price competitiveness (75 percent) alongside compliance with administrative data formatting (5 percent), EDI capability (5 percent), administrative-fee agreement (5 percent), and fixed pricing (10 percent). Vendors must maintain commercial general liability insurance of $5,000,000 per occurrence and network security and privacy liability of $2,000,000, maintain relationships with at least two of the three authorized wholesalers, and accept a 3 percent administrative fee on all contract purchases with performance penalties of $200 to $1,500 per violation for late reporting or missed onboarding timelines.